Omni surgical system reduces IOP, medication use over 3 years
Click Here to Manage Email Alerts
Stand-alone use of the Omni surgical system reduced IOP and the need for IOP-lowering medications at 36 months in adults with open-angle glaucoma, according to a press release from Sight Sciences.
Thirty-eight eyes of 26 patients with open-angle glaucoma were followed up between 1 day and 36 months after treatment with the Omni system. All eyes experienced a mean IOP reduction of at least 20% at 36 months. After medication washout, mean IOP was 24.6 ± 3.2 mm Hg at baseline, decreasing to 14.5 ± 1.7 mm Hg at 12 months, 14.2 ± 2 mm Hg at 24 months and 15 ± 1.9 mm Hg at 36 months.
In addition, the mean number of IOP-lowering medications was reduced from 1.9 ± 0.7 at baseline to 0.4 ± 0.6 at 12 months, 0.6 ± 0.7 at 24 months and 0.5 ± 0.7 at 36 months.
A “minimal” number of adverse events that resolved without intervention were reported. A secondary IOP-lowering intervention was needed in one eye.
“The Omni surgical system is supported by a robust clinical development program, which includes this treatment evaluation over 3 years in patients with open-angle glaucoma. These results highlight the long-term effectiveness and strong safety profile of the Omni surgical system. This non-implantable procedure has shown effectiveness without the known IOP-lowering assistance of cataract surgery,” Paul Badawi, co-founder and CEO of Sight Sciences, said in the release.
Read more about
Click Here to Manage Email Alerts